BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 23167406)

  • 1. Comparison of vinorelbine, ifosfamide and cisplatin (NIP) and etoposide and cisplatin (EP) for treatment of advanced combined small cell lung cancer (cSCLC) patients: a retrospective study.
    Luo J; Wu FY; Li AW; Zheng D; Liu JM
    Asian Pac J Cancer Prev; 2012; 13(9):4703-6. PubMed ID: 23167406
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vinorelbine, ifosfamide, and cisplatin combination as salvage chemotherapy in advanced non-small cell lung cancer.
    Song SY; Kim WS; Kim K; Jung CW; Im YH; Kim HJ; Kang WK; Lee HG; Kwon OJ; Rhee CH; Park CH; Park K
    Jpn J Clin Oncol; 2003 Oct; 33(10):509-13. PubMed ID: 14623918
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Belotecan/cisplatin versus etoposide/cisplatin in previously untreated patients with extensive-stage small cell lung carcinoma: a multi-center randomized phase III trial.
    Oh IJ; Kim KS; Park CK; Kim YC; Lee KH; Jeong JH; Kim SY; Lee JE; Shin KC; Jang TW; Lee HK; Lee KY; Lee SY
    BMC Cancer; 2016 Aug; 16(1):690. PubMed ID: 27566413
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Etoposide-cisplatin alternating with vinorelbine-cisplatin versus etoposide-cisplatin alone in patients with extensive disease combined with small cell lung cancer.
    Zhang J; Qi HW; Zheng H; Chen M; Zhu J; Xie HK; Ni J; Xu JF; Zhou CC
    Asian Pac J Cancer Prev; 2014; 15(10):4159-63. PubMed ID: 24935363
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Efficiency and adverse effects of the effective therapy applying etoposide + cisplatin and its subsequent maintenance therapy with different durations in patients with small cell lung cancer].
    Yang CL; Ma LX; Sun SY; Cui HX; Li ZL; Cheng Y
    Zhonghua Zhong Liu Za Zhi; 2016 Jun; 38(6):454-9. PubMed ID: 27346404
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cisplatin-based three drugs combination (NIP) as induction and adjuvant treatment in locally advanced non-small cell lung cancer: final results.
    Gottfried M; Ramlau R; Krzakowski M; Ziolo G; Olechnowicz H; Koubkova L; Dahabreh J; Szczesna A; Vivanco GL; Perng RP; Carpagnano F; Leong SS; Fittipaldo A; De Almeida C; Aubert D; Grunenwald D
    J Thorac Oncol; 2008 Feb; 3(2):152-7. PubMed ID: 18303436
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized phase III trial of amrubicin/cisplatin versus etoposide/cisplatin as first-line treatment for extensive small-cell lung cancer.
    Sun Y; Cheng Y; Hao X; Wang J; Hu C; Han B; Liu X; Zhang L; Wan H; Xia Z; Liu Y; Li W; Hou M; Zhang H; Xiu Q; Zhu Y; Feng J; Qin S; Luo X
    BMC Cancer; 2016 Apr; 16():265. PubMed ID: 27061082
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A comparative study on etoposide combined with lobaplatin or cisplatin in the first-line treatment of extensive-stage small cell lung cancer.
    Li S; Liang Y; Wu Y; Huang Z; Lin Y; Yang Z; Chen H; Wu A
    J BUON; 2020; 25(3):1490-1496. PubMed ID: 32862595
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cisplatin and vinorelbine followed by ifosfamide plus epirubicin vs the opposite sequence in advanced unresectable stage III and metastatic stage IV non-small-cell lung cancer: a prospective randomized study of the Southern Italy Oncology Group (GOIM).
    Colucci G; Gebbia V; Galetta D; Riccardi F; Cariello S; Gebbia N
    Br J Cancer; 1997; 76(11):1509-17. PubMed ID: 9400950
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vinorelbine, ifosfamide and cisplatin in advanced non-small cell lung cancer.
    Tan EH; Ang PT; Wee J; Fong KW; Leong SS; Khoo KS
    Acta Oncol; 1999; 38(5):619-22. PubMed ID: 10427951
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Carboplatin versus cisplatin in combination with etoposide in the first-line treatment of small cell lung cancer: a pooled analysis.
    Jiang S; Huang L; Zhen H; Jin P; Wang J; Hu Z
    BMC Cancer; 2021 Dec; 21(1):1308. PubMed ID: 34876060
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Outcomes of small cell lung cancer patients treated with cisplatin-etoposide versus carboplatin-etoposide.
    Karam I; Jiang SY; Khaira M; Lee CW; Schellenberg D
    Am J Clin Oncol; 2015 Feb; 38(1):51-4. PubMed ID: 23563211
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Real-world evaluation of first-line treatment of extensive-stage small-cell lung cancer with atezolizumab plus platinum/etoposide: a focus on patients with brain metastasis.
    Chen H; Ma X; Liu J; Yang Y; He Y; Fang Y; Wang L; Fang J; Zhao J; Zhuo M
    Clin Transl Oncol; 2024 Jul; 26(7):1664-1673. PubMed ID: 38329610
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Outcomes of Platinum-Sensitive Small-Cell Lung Cancer Patients Treated With Platinum/Etoposide Rechallenge: A Multi-Institutional Retrospective Analysis.
    Genestreti G; Tiseo M; Kenmotsu H; Kazushige W; Di Battista M; Cavallo G; Carloni F; Bongiovanni A; Burgio MA; Casanova C; Metro G; Scarpi E; Korkmaz T; Selcuk S; Roopa K; Califano R
    Clin Lung Cancer; 2015 Nov; 16(6):e223-8. PubMed ID: 25983005
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Etoposide plus cisplatin with or without the combination of 4'-epidoxorubicin plus cyclophosphamide in treatment of extensive small-cell lung cancer: a French Federation of Cancer Institutes multicenter phase III randomized study.
    Pujol JL; Daurès JP; Rivière A; Quoix E; Westeel V; Quantin X; Breton JL; Lemarié E; Poudenx M; Milleron B; Moro D; Debieuvre D; Le Chevalier T
    J Natl Cancer Inst; 2001 Feb; 93(4):300-8. PubMed ID: 11181777
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Six versus four or five cycles of first-line etoposide and platinum-based chemotherapy combined with thoracic radiotherapy in patients with limited-stage small-cell lung cancer: A propensity score-matched analysis of a prospective randomized trial.
    Yu TT; Hu X; Liufu WJ; Niu SQ; Lian HM; Ma HL; Wang J; Bao Y; Chen M; Peng F
    Cancer Med; 2024 Apr; 13(8):e7215. PubMed ID: 38659392
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A multicenter, randomized, phase 3 trial comparing fixed dose versus toxicity-adjusted dose of cisplatin + etoposide in extensive small-cell lung cancer (SCLC) patients: The Small-cell-lung cancer Toxicity Adjusted Dosing (STAD-1) trial.
    Morabito A; Daniele G; Costanzo R; Favaretto AG; Filipazzi V; Rossi A; Gebbia V; Castiglione F; Cavanna L; Maiello E; Sandomenico C; Bonanno L; Piazza E; Maione P; Piccirillo MC; Di Maio M; Rocco G; Gallo C; Perrone F; Gridelli C
    Lung Cancer; 2017 Jun; 108():15-21. PubMed ID: 28625627
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Phase I Study of Etoposide and Cisplatin Chemotherapy Dose Escalation 
with Concurrent Twice-daily Radiotherapy for Patients 
with Limited-stage Small Cell Lung Cancer].
    You J; Yu H; Song M; Shi C; Wang X; Zheng Y; Yu R; Shi A; Zhu G
    Zhongguo Fei Ai Za Zhi; 2017 Jan; 20(1):55-60. PubMed ID: 28103974
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II study of cisplatin plus etoposide and bevacizumab for previously untreated, extensive-stage small-cell lung cancer: Eastern Cooperative Oncology Group Study E3501.
    Horn L; Dahlberg SE; Sandler AB; Dowlati A; Moore DF; Murren JR; Schiller JH
    J Clin Oncol; 2009 Dec; 27(35):6006-11. PubMed ID: 19826110
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [A randomized controlled study of chemotherapy: etoposide combined with oxaliplatin or cisplatin regimens in the treatment of extensive-stage small cell lung cancer in elderly patients].
    Pu D; Hou M; Li Z; Zeng X
    Zhongguo Fei Ai Za Zhi; 2013 Jan; 16(1):20-4. PubMed ID: 23327869
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.